Tuberculosis - Pipeline Insight, 2024

Tuberculosis - Pipeline Insight, 2024

DelveInsight’s, “Tuberculosis – Pipeline Insight, 2024,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Tuberculosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Tuberculosis Understanding

Tuberculosis: Overview

Tuberculosis (TB) is a bacterial infection spread through inhaling tiny droplets from the coughs or sneezes of an infected person. Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but TB bacteria can attack any part of the body such as the kidney, spine, and brain. Not everyone infected with TB bacteria becomes sick. As a result, two TB-related conditions exist: latent TB infection (LTBI) and TB disease.

Typical symptoms of TB include:

• a persistent cough that lasts more than 3 weeks and usually brings up phlegm, which may be bloody
• weight loss
• night sweats
• high temperature
• tiredness and fatigue
• loss of appetite
• swellings in the neck.

If not treated properly, TB disease can be fatal. With treatment, TB can almost always be cured. A course of antibiotics will usually need to be taken for 6 months. Several different antibiotics are used because some forms of TB are resistant to certain antibiotics.

Tuberculosis Emerging Drugs Chapters

This segment of the Tuberculosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tuberculosis Emerging Drugs

• Telacebec (Q203): Qurient Co

Telacebec (Q203) is one of the first candidates getting close to forming new universal regimen. Telacebec (Q203) is an orally active small molecule drug candidate that blocks Mycobacterium tuberculosis growth by inhibiting cytochrome bc1 complex, leading to the depletion of adenosine triphosphate (ATP) synthesis of M. tuberculosis. Telacebec (Q203) shows good synergy with bedaquiline in murine chronic infection model, indicating promising potential for new drug regimen. The drug is currently in phase 2 stage of development.

• VPM1002: Serum Institute of India

VPM1002 facilitates mycobacterial antigens being released into the cytosol while also triggering autophagy, inflammasome activation, and apoptosis, because of antigens and bacterial DNA being released into the cytosol of the host cell due to Listeriolysin O expression in this vaccine. Mycobacterial antigen accessing the cytosol also improves antigen presentation. The ability for mycobacterial antigens to reach the cytosol is due to this vaccine being engineered to secrete Hly which perforates phagosomal membranes. Currently, it is in phase III stage of development for the treatment of Tuberculosis.

Further product details are provided in the report……..

Tuberculosis: Therapeutic Assessment

This segment of the report provides insights about the different Tuberculosis drugs segregated based on following parameters that define the scope of the report, such as:

● Major Players in Tuberculosis

There are approx. 35+ key companies which are developing the therapies for Tuberculosis. The companies which have their Tuberculosis drug candidates in the mid to advanced stage, i.e. Phase III include, Qurient Co

Phases

DelveInsight’s report covers around 35+ products under different phases of clinical development like

• Late-stage products (Phase III )
• Mid-Stage products (Phase II)
• Early-stage products ( Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

● Route of Administration

Tuberculosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Oral

● Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Peptide
• Antibiotics

● Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tuberculosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tuberculosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tuberculosis drugs.

Report Highlights

● The companies and academics are working to assess challenges and seek opportunities that could influence Tuberculosis R&D. The therapies under development are focused on novel approaches to treat/improve Tuberculosis.

Tuberculosis Report Insights

• Tuberculosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Tuberculosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Tuberculosis drugs?
• How many Tuberculosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tuberculosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tuberculosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Tuberculosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Serum Institute of India Pvt. Ltd.
• AnHui Longcom Biologic Pharmacy
• Biofabri, S.L
• Immunitor LLC
• Shanghai Jiatan Pharmatech
• GlaxoSmithKline
• Archivel Farma S.L.
• LegoChem Biosciences
• Quratis Inc
• Aeras
• Qurient Co.
• Sequella, Inc.
• Otsuka Pharmaceutical
• Vaxil Biotherapeutics
• Faron Pharmaceuticals
• Tianjin CanSino Biotechnology
• Global Alliance for TB Drug Development
• Spero Therapeutics

Key Products

• VPM1002
• MTBVAC|
• ESAT6-CFP10
• V7
• WX-081
• GSK 692342
• GSK3036656
• RUTI
• LCB01-0371
• ID 93
• AERAS-404
• Telacebec
• Sutezolid
• OPC-167832
• Tuberculosis vaccine
• TBA 7371
• TBAJ-876
• SPR720